Finance Halo
Company Overview
Hologic, Inc. (HOLX) is a global leader in women's health, focusing on diagnostics, medical imaging, and surgical products. The company's core business segments include Diagnostics, Breast Health, and Skeletal Health, with a strong emphasis on innovative solutions that improve patient outcomes. Hologic holds a significant market position in its key product areas and is recognized for its commitment to advancing women's healthcare worldwide.
Price Action Analysis
Daily Chart (3-month): The daily chart shows HOLX trading within a defined range for much of the past three months, indicating a consolidation pattern. Recently, the price has shown signs of an upward movement, attempting to break above this consolidation. Volume analysis on the daily chart reveals increased activity during these upward price movements, suggesting growing interest and potential accumulation. The candlestick structures show a series of higher lows and attempts to make higher highs, characteristic of a potential breakout scenario.
Weekly Chart (2-year): The weekly chart provides a longer-term perspective, illustrating a significant downtrend from a peak in early 2022, followed by a period of stabilization and an attempted recovery. The recent price action on the weekly chart appears to be breaking out of a more extended consolidation phase that followed the major decline. Volume on the weekly chart has been more subdued but shows sporadic spikes that coincide with upward price momentum, indicating potential investor interest during these breakout attempts. Key resistance levels from prior peaks in the 2-year range are critical to watch.
News & Catalysts
Hologic (HOLX) has recently achieved a new 52-week high of $75.49 on March 3, 2026. However, analyst sentiment appears mixed, with a majority holding a "Hold" rating and a consensus price target of $78.42.
- Morgan Stanley raised its price target to $76 from $69 while maintaining an "Equal Weight" rating. (Source: Various Financial News Outlets, March 2026)
- BNP Paribas Exane downgraded HOLX from "Strong Buy" to "Hold" with a price target of $79. (Source: Various Financial News Outlets, March 2026)
- Argus downgraded the stock from "Buy" to "Hold". (Source: Various Financial News Outlets, March 2026)
Recent company-specific news includes the FDA approval for Hologic's Aptima® HPV Assay primary screening option on February 4, 2026. This approval expands the company's offerings in cervical health. Furthermore, Hologic reported its first-quarter fiscal 2026 earnings on January 29, 2026, where it fell short of analyst expectations for both revenue and EPS. Despite the earnings miss, the Aptima HPV Assay's FDA approval and its unique mRNA-based technology for detecting high-risk HPV infections are significant positive developments. These events likely influenced recent price action by creating a mixed sentiment, with the stock reacting positively to the FDA approval while showing some hesitation due to the earnings report.
Fondamental analysis
Key Financial Metrics
| Metric | Value |
|---|---|
| Current Price | $75.67 |
| Market Cap | $16.89B |
| Forward P/E Ratio | 15.59 |
| Return on Equity | 10.86% |
| Profit Margins | 13.18% |
| Gross Margins | 60.38% |
| Operating Margins | 22.99% |
| Debt to Equity | 48.05% |
| Dividend Yield | N/A |
Financial Performance (Annual)
| Fiscal Year End | Total Revenue | Gross Profit | Operating Income | Net Income | Diluted EPS |
|---|---|---|---|---|---|
| 2023-09-30 | $4.03B | $2.07B | $0.79B | $0.46B | $1.83 |
| 2024-09-30 | $4.03B | $1.52B | $1.34B | $0.79B | $3.32 |
| 2025-09-30 | $4.10B | $1.70B | $1.17B | $0.57B | $2.49 |
Financial Performance (Quarterly - Latest Reported)
| Quarter End | Total Revenue | Gross Profit | Operating Income | Net Income | Diluted EPS |
|---|---|---|---|---|---|
| 2025-12-31 | $1.05B | $0.59B | $0.24B | $0.18B | $0.79 |
| 2025-09-30 | $1.05B | $0.58B | $0.25B | $0.19B | $0.83 |
Earnings and Estimates
- EPS Trend: Recent quarterly EPS has shown some fluctuation, with the latest reported quarter at $0.79 and estimates for the next quarter at $1.11. Annual EPS estimates suggest a dip in FY2025 compared to FY2024.
- Analyst Estimates:
- Earnings: Analysts have revised EPS estimates downwards for upcoming quarters and the current fiscal year. For the current quarter (0q), the average EPS estimate is $1.05, with 4 downward revisions in the last 30 days. For the next fiscal year (+1y), the average EPS estimate is $3.78.
- Revenue: Revenue estimates show a slight increase for the upcoming quarters and fiscal year. For the current quarter (0q), the average revenue estimate is $1.03B. For the next fiscal year (+1y), the average revenue estimate is $4.46B.
- Analyst Recommendations: The summary indicates a strong "Hold" consensus, with 16 out of 16 analysts recommending a "Hold" rating for the past two months.
- Analyst Price Targets: The consensus price target from 10 analysts is $76.60, with a range of $76.00 to $78.00. This is slightly above the current market price.
Key Takeaways: Hologic demonstrates solid gross and operating margins, indicating efficient operations. However, recent quarterly earnings have missed expectations, and analysts have revised estimates downwards, contributing to a "Hold" consensus. Despite these headwinds, the company has a strong balance sheet with manageable debt levels and substantial cash reserves. The forward P/E ratio suggests that the stock may be reasonably valued for future growth.
Market & Sentiment Context
Market Context: The broader market sentiment is mixed, with ongoing concerns about inflation and interest rate policies influencing sector rotations. Healthcare, as a defensive sector, can be resilient, but companies within it are still subject to specific industry trends and competitive pressures. The medical technology space, where Hologic operates, is generally favored for its innovation and demographic tailwinds, but execution and regulatory approvals are critical.
Catalysts:
- FDA Approval: The recent FDA approval for the Aptima® HPV Assay is a significant catalyst, expanding Hologic's diagnostic capabilities and market reach in women's health.
- Product Innovation: Continued investment in R&D and successful product launches are crucial for Hologic's sustained growth and competitive advantage.
- Earnings Performance: Future earnings reports will be closely watched to see if the company can meet or exceed analyst expectations, especially after the recent miss.
Investor Sentiment: The price action suggests cautious optimism. The breakout attempt on increased volume indicates that some investors are accumulating the stock, anticipating a positive move. However, the mixed analyst ratings and downward EPS revisions temper this sentiment. The recent 52-week high suggests positive momentum, but the sustainability of this move depends on overcoming key resistance levels and delivering on future growth prospects.
Investment Outlook
Hologic presents a mixed but potentially promising investment case. The company operates in a stable and growing sector with a strong product portfolio, particularly in women's diagnostics. The recent FDA approval for its HPV assay is a significant positive development. However, recent financial results and downward earnings revisions have led to a cautious analyst outlook, reflected in the predominant "Hold" recommendations.
The stock is currently trading near its 52-week high, suggesting recent positive price momentum. If HOLX can sustain its upward trajectory and break convincingly above key resistance levels, it could signal a continuation of its recovery. The key will be Hologic's ability to translate its product innovations and market position into consistent revenue and earnings growth that satisfies analyst expectations.
Key Buy/Sell Levels
The current price for Hologic, Inc. (HOLX) is $75.67.
Support Levels
- $74.00 - $74.50: This zone represents a key support area, identified by previous consolidation lows on the daily chart and coinciding with a prior breakout area. This level has been touched recently.
Resistance Levels
- $76.00 - $77.00: This is a critical resistance zone, currently being tested. It aligns with the upper boundary of the recent consolidation and the stock's 52-week high. A decisive move above this level, supported by strong volume, would be a significant bullish signal.
- $78.00 - $80.00: This area represents a more significant resistance level, corresponding to peaks seen on the weekly chart over the past two years. Breaking through this zone would indicate a strong continuation of an upward trend.
Trendline Analysis:
- A horizontal line at approximately $76.00 (drawing line from 2026-02-26 00:00:00 at $75.40 to 2026-05-26 00:00:00 at $76.00) should be drawn to mark the immediate resistance. This level has been touched and may present an initial hurdle.
- Another horizontal line at approximately $74.25 (drawing line from 2026-02-04 00:00:00 at $74.40 to 2026-05-04 00:00:00 at $74.25) can be drawn to indicate a significant support level from prior price action. This level has been tested.
Summary & Takeaways
Hologic, Inc. (HOLX) is showing signs of a potential breakout from a consolidation pattern, reaching a new 52-week high. The company operates in the vital women's health sector, bolstered by recent FDA approval for its HPV assay.
Key Strengths:
- Strong market position in women's health.
- Innovative product pipeline, evidenced by the recent FDA approval.
- Solid gross and operating margins.
- Breakout attempt on increasing volume.
Key Weaknesses/Concerns:
- Mixed analyst sentiment with a predominant "Hold" rating.
- Recent quarterly earnings miss and downward EPS revisions.
- Stock currently testing a significant resistance level around $76.00-$77.00.
Outlook: The investment outlook for HOLX is cautiously optimistic. A decisive move above the $76.00-$77.00 resistance level, coupled with sustained volume, could propel the stock higher towards the $78.00-$80.00 range. Investors will be closely monitoring upcoming earnings reports and analyst commentary for confirmation of future growth and an improvement in sentiment. The current support at $74.00-$74.50 needs to hold to maintain the bullish breakout thesis.